# Cardeas Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardeas-pharma

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Website: www.cardeaspharma.com
- Total disclosed funding: $46M
- Latest round: Series B (Apr 9, 2015)
- Investors on record: 5

## About

Cardeas Pharma Corp. is a pharmaceutical company focused on the development and commercialization of innovative therapies that address critical health challenges, particularly in chronic conditions and rare diseases.Cardeas Pharma Corp. specializes in advanced pharmaceutical products aimed at treating complex health issues. The company was founded in Seattle, US, and has undergone significant developments in its strategy. In April 2015, Cardeas raised USD 3.50 mn in Series B funding from Avalon Ventures and Novo Holdings, marking its latest financial milestone. The company has completed a total of four deals, achieving a current valuation of USD 51.51 mn.Cardea Pharma specializes in the development and commercialization of advanced pharmaceutical products aimed at addressing critical health challenges. The company's core offerings include a range of innovative therapies designed to enhance patient outcomes across various therapeutic areas. These products are particularly focused on treating chronic conditions and rare diseases, leveraging cutting-edge technologies to improve efficacy and patient adherence. Cardea Pharma’s client base consists of healthcare providers, pharmaceutical distributors, and hospitals across North America and Europe, where they aim to serve both patients and healthcare professionals with high-quality solutions. The company launched its flagship products in the last few years, achieving significant milestones in clinical trials that demonstrate their effectiveness and safety profiles.Cardea Pharma generates revenue through a diversified transaction model that includes both direct-to-consumer sales and partnerships with healthcare institutions. The company's revenue structure is primarily based on the sale of its proprietary pharmaceuticals, which are marketed to hospitals and clinics. Transactions typically involve purchase agreements with healthcare providers that ensure a steady supply of their flagship products. Additionally, partnerships with pharmaceutical wholesalers enhance the distribution network, facilitating broader access to their therapies. The pricing plans for these products are structured to reflect the value provided to healthcare professionals and patients, ensuring that the therapies remain accessible while supporting the company’s growth objectives.Cardeas Pharma plans to leverage the recent USD 3.50 mn raised in Series B funding to support the development of new products and enhance its market presence. The company is focusing on launching innovative therapies designed to address chronic conditions and rare diseases, with anticipated releases within the next few years. Furthermore, Cardeas aims to expand its reach into new geographic markets, specifically targeting Europe and additional regions in North America by 2025, to widen access to its products and increase its client base.

## Funding rounds

- Series B, Apr 9, 2015, $3.5M — Avalon Ventures, Novo Holdings
- Series B, May 22, 2013, $34M — Avalon Ventures, H.I.G. BioHealth Partners, Devon Park Bioventures, WRF Capital, Novo Holdings
- Series A, Jun 7, 2012, $8.5M — Avalon Ventures, Devon Park Bioventures, WRF Capital, Novo Holdings

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B
- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series A, Series B
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A, Series B
- Novo Holdings — Series A, Series B
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series B